Difficult-To-Treat Juvenile Idiopathic Arthritis: Current and Future Options.

about

Identification of potential peripheral blood diagnostic biomarkers for patients with juvenile idiopathic arthritis by bioinformatics analysis.

P2860

Q39171371-3C864A0F-66B8-430C-AE90-14CF433A8FFC

P2860

Difficult-To-Treat Juvenile Idiopathic Arthritis: Current and Future Options.

Item

http://www.wikidata.org/entity/Q38759376

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Difficult-To-Treat Juvenile Idiopathic Arthritis: Current and Future Options.

@en

type

Item

label

Difficult-To-Treat Juvenile Idiopathic Arthritis: Current and Future Options.

@en

prefLabel

Difficult-To-Treat Juvenile Idiopathic Arthritis: Current and Future Options.

@en

P1476

Difficult-To-Treat Juvenile Idiopathic Arthritis: Current and Future Options.

@en

P2093

Federico Bertini

http://www.w3.org/2001/XMLSchema#string

Ilaria Pagnini

http://www.w3.org/2001/XMLSchema#string

Rolando Cimaz

http://www.w3.org/2001/XMLSchema#string

P2860

Rituximab for rheumatoid arthritis

Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis.

Adalimumab with or without methotrexate in juvenile rheumatoid arthritis.

Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phas

Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis.

Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial.

Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy.

Selective JAK inhibitors in development for rheumatoid arthritis.

P2888

s40272-016-0164-6

P304

101-108

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40272-016-0164-6

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-03-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1023500363

http://www.w3.org/2001/XMLSchema#string

P698

26939782

http://www.w3.org/2001/XMLSchema#string

P921

juvenile rheumatoid arthritis

Difficult-To-Treat Juvenile Idiopathic Arthritis: Current and Future Options.

about

P2860

P2860

Difficult-To-Treat Juvenile Idiopathic Arthritis: Current and Future Options.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P921